AccScience Publishing / MI / Online First / DOI: 10.36922/mi.7947
Submit to MI
Cite this article
12
Download
195
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

The application of a herpes simplex virus Type I vector for transgenic therapy

Chunfu Zheng1*
Show Less
1 Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Canada
MI, 7947 https://doi.org/10.36922/mi.7947
Submitted: 18 December 2024 | Revised: 13 February 2025 | Accepted: 19 February 2025 | Published: 4 March 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

The key to successful gene therapy is to effectively transfer genes to target cells and control the effective expression of genes to avoid expression in non-target tissues. At present, there are two common methods of gene therapy: non-replicating viruses and viral vectors. The use of non-replicating viruses as vectors often limits the efficiency of gene transfer and is unsatisfactory for clinical application. In contrast, replicative viral vectors can deliver genes from a small number of cells to neighboring cells, significantly improve the efficiency of gene delivery, and stably and persistently express exogenous genes. As a result, the investigation and application of viral vectors are recommended. Herpes simplex virus Type I-derived vectors have gradually become important biological treatments due to their wide host range, integration of long fragments of exogenous DNA, neurotropism, and various animal models.

Keywords
Herpes simplex virus Type I
Gene therapy
Vectors
Transgenic technology
Funding
This work was supported by the National Natural Science Foundation of China (82072263).
Conflict of interest
Chunfu Zheng is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. The author also declared that he has no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. McGeoch DJ, Dalrymple MA, Davison AJ, et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988;69(Pt 7):1531-1574. doi: 10.1099/0022-1317-69-7-1531

 

  1. Roizman B, Baines J. The diversity and unity of Herpesviridae. Comp Immunol Microbiol Infect Dis. 1991;14(2):63-79. doi: 10.1016/0147-9571(91)90122-t

 

  1. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26(3):541-553; quiz 554-5.

 

  1. Marozin S, Prank U, Sodeik B. Herpes simplex virus type 1 infection of polarized epithelial cells requires microtubules and access to receptors present at cell-cell contact sites. J Gen Virol. 2004;85(Pt 4):775-786. doi: 10.1099/vir.0.19530-0

 

  1. Babb R, Huang CC, Aufiero DJ, Herr W. DNA recognition by the herpes simplex virus transactivator VP16: A novel DNA-binding structure. Mol Cell Biol. 2001;21(14):4700-4712. doi: 10.1128/MCB.21.14.4700-4712.2001

 

  1. Watanabe D. Medical application of herpes simplex virus. J Dermatol Sci. 2010;57(2):75-82. doi: 10.1016/j.jdermsci.2009.10.014

 

  1. Boehmer PE, Lehman IR. Herpes simplex virus DNA replication. Annu Rev Biochem. 1997;66:347-384. doi: 10.1146/annurev.biochem.66.1.347

 

  1. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci U S A. 1996;93(21):11307-11312. doi: 10.1073/pnas.93.21.11307

 

  1. Elliott G, O’Hare P. Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division. J Virol. 2000;74(5):2131-2141. doi: 10.1128/jvi.74.5.2131-2141.2000

 

  1. Jackson SA, DeLuca NA. Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proc Natl Acad Sci U S A. 2003;100(13):7871-7876. doi: 10.1073/pnas.1230643100

 

  1. Steiner I, Kennedy PG. Molecular biology of herpes simplex virus type 1 latency in the nervous system. Mol Neurobiol. 1993;7(2):137-159. doi: 10.1007/BF02935640

 

  1. Roizman B, Whitley RJ. The nine ages of herpes simplex virus. Herpes. 2001;8(1):23-27.

 

  1. Rouse BT. Pathogenesis of the herpesviruses. Lab Anim Sci. 1993;43(1):11-14.

 

  1. Aurelian L. HSV-induced apoptosis in herpes encephalitis. Curr Top Microbiol Immunol. 2005;289:79-111. doi: 10.1007/3-540-27320-4_4

 

  1. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513-1518. doi: 10.1016/S0140-6736(00)04638-9

 

  1. Daheshia M, Feldman LT, Rouse BT. Herpes simplex virus latency and the immune response. Curr Opin Microbiol. 1998;1(4):430-435. doi: 10.1016/s1369-5274(98)80061-1

 

  1. Arduino PG, Porter SR. Herpes simplex virus type 1 infection: Overview on relevant clinico-pathological features. J Oral Pathol Med. 2008;37(2):107-121. doi: 10.1111/j.1600-0714.2007.00586.x

 

  1. Roizman B. HSV gene functions: What have we learned that could be generally applicable to its near and distant cousins? Acta Virol. 1999;43(2-3):75-80.

 

  1. Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B. Friendly fire: Redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002;8(9):551-563. doi: 10.1046/j.1469-0691.2002.00432.x.

 

  1. Goins WF, Wolfe D, Krisky DM, et al. Delivery using herpes simplex virus: An overview. Methods Mol Biol. 2004;246:257-299. doi: 10.1385/1-59259-650-9:257

 

  1. Epstein AL. HSV-1-derived recombinant and amplicon vectors for preventive or therapeutic gene transfer: An overview. Gene Ther. 2005;12 Suppl 1:S153.

 

  1. Maguire-Zeiss KA, Bowers WJ, Federoff HJ. HSV vector-mediated gene delivery to the central nervous system. Curr Opin Mol Ther. 2001;3(5):482-490.

 

  1. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol. 2004;58:253-271. doi: 10.1146/annurev.micro.58.030603.123709

 

  1. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: A review. Rev Med Virol. 2000;10(1):17-30. doi: 10.1002/(sici)1099-1654(200001/02)10:1<17:aid-rmv2 58>3.0.co;2-g

 

  1. Niranjan A, Wolfe D, Fellows W, et al. Gene transfer to glial tumors using herpes simplex virus. Methods Mol Biol. 2004;246:323-337. doi: 10.1385/1-59259-650-9:323

 

  1. Karpoff HM, Kooby D, D’Angelica M, et al. Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production. Cancer Gene Ther. 2000;7(4):581-588. doi: 10.1038/sj.cgt.7700135

 

  1. Kaur A, Sanford HB, Garry D, et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology. 2007;357(2):199-214. doi: 10.1016/j.virol.2006.08.007

 

  1. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16(15):4005-4015. doi: 10.1158/1078-0432.CCR-10-0196

 

  1. Epstein AL. HSV-1-derived amplicon vectors: Recent technological improvements and remaining difficulties-a review. Mem Inst Oswaldo Cruz. 2009;104(3):399-410. doi: 10.1590/s0074-02762009000300002

 

  1. Epstein AL. HSV-1-based amplicon vectors: Design and applications. Gene Ther. 2005;12 Suppl 1:S154-S158. doi: 10.1038/sj.gt.3302617

 

  1. Wang S, Fraefel C, Breakefield X. HSV-1 amplicon vectors. Methods Enzymol. 2002;346:593-603. doi: 10.1016/s0076-6879(02)46079-x

 

  1. Marconi P, Argnani R, Berto E, Epstein AL, Manservigi R. HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol. 2009;655:118-144.

 

  1. Ho DY. Amplicon-based herpes simplex virus vectors. Methods Cell Biol. 1994;43 Pt A:191-210. doi: 10.1016/s0091-679x(08)60604-4.

 

  1. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther. 2001;3(4):591-601. doi: 10.1006/mthe.2001.0294

 

  1. Zaupa C, Revol-Guyot V, Epstein AL. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther. 2003;14(11):1049-1063. doi: 10.1089/104303403322124774

 

  1. Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon vectors: A promising and versatile tool for gene delivery. Expert Opin Biol Ther. 2007;7(7):975-995. doi: 10.1517/14712598.7.7.975

 

  1. Kasai K, Saeki Y. DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids. Curr Gene Ther. 2006;6(3):303-314. doi: 10.2174/156652306777592081

 

  1. Logvinoff C, Epstein AL. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus. Hum Gene Ther. 2001;12(2):161-167. doi: 10.1089/104303401750061221

 

  1. Saydam O, Glauser DL, Fraefel C. Construction and packaging of herpes simplex virus/adeno-associated virus (HSV/AAV) Hybrid amplicon vectors. Cold Spring Harb Protoc. 2012;2012(3):352-356. doi: 10.1101/pdb.prot068114

 

  1. Brooks AI, Cory-Slechta DA, Bowers WJ, Murg SL, Federoff HJ. Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. Hum Gene Ther. 2000;11(17):2341-2352. doi: 10.1089/104303400750038453

 

  1. Harvey BK, Chang CF, Chiang YH, et al. HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp Neurol. 2003;183(1):47-55. doi: 10.1016/s0014-4886(03)00080-3.

 

  1. DeLuca NA, Schaffer PA. Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4. Mol Cell Biol. 1985;5(8):1997-2008. doi: 10.1128/mcb.5.8.1997-2008.1985

 

  1. Kaplitt MG, Makimura H. Defective viral vectors as agents for gene transfer in the nervous system. J Neurosci Methods. 1997;71(1):125-132. doi: 10.1016/s0165-0270(96)00132-x

 

  1. Wood MJ, Byrnes AP, Kaplitt MG, et al. Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: Implications for gene targeting. Exp Neurol. 1994;130(1):127-140. doi: 10.1006/exnr.1994.1192

 

  1. Kaplitt MG, Pfaff DW. Viral vectors for gene delivery and expression in the CNS. Methods. 1996;10(3):343-350. doi: 10.1006/meth.1996.0112

 

  1. Ho DY, Fink SL, Lawrence MS, et al. Herpes simplex virus vector system: Analysis of its in vivo and in vitro cytopathic effects. J Neurosci Methods. 1995;57(2):205-215. doi: 10.1016/0165-0270(94)00150-f

 

  1. Krisky DM, Wolfe D, Goins WF, et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 1998;5(12):1593-1603. doi: 10.1038/sj.gt.3300766

 

  1. Krisky DM, Marconi PC, Oligino TJ, et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 1998;5(11):1517-1530. doi: 10.1038/sj.gt.3300755

 

  1. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996;15(17):4759-4766.

 

  1. Daikoku T, Yamamoto N, Maeno K, Nishiyama Y. Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells. J Gen Virol. 1991;72(Pt 6):1441-1444. doi: 10.1099/0022-1317-72-6-1441

 

  1. Becker Y, Tavor E, Asher Y, Berkowitz C, Moyal M. Effect of herpes simplex virus type-1 UL41 gene on the stability of mRNA from the cellular genes: Beta-actin, fibronectin, glucose transporter-1, and docking protein, and on virus intraperitoneal pathogenicity to newborn mice. Virus Genes. 1993;7(2):133-143. doi: 10.1007/BF01702393

 

  1. Broberg EK, Hukkanen V. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. Curr Gene Ther. 2005;5(5):523-530. doi: 10.2174/156652305774329267

 

  1. Talloczy Z, Virgin HW 4th, Levine B. PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy. 2006;2(1):24-29. doi: 10.4161/auto.2176

 

  1. Cheng G, Feng Z, He B. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein. J Virol. 2005;79(3):1379-1388. doi: 10.1128/JVI.79.3.1379-1388.2005

 

  1. Epstein AL, Marconi P, Argnani R, Manservigi R. HSV-1- derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther. 2005;5(5):445-458. doi: 10.2174/156652305774329285

 

  1. Kaufman HL, Bines SD. OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010;6(6):941-949. doi: 10.2217/fon.10.66

 

  1. Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010;21(9):1119-1128. doi: 10.1089/hum.2010.020

 

  1. Kopp M, Klupp BG, Granzow H, Fuchs W, Mettenleiter TC. Identification and characterization of the pseudorabies virus tegument proteins UL46 and UL47: Role for UL47 in virion morphogenesis in the cytoplasm. J Virol. 2002;76(17):8820-8833. doi: 10.1128/jvi.76.17.8820-8833.2002

 

  1. Tanaka M, Nishiyama Y, Sata T, Kawaguchi Y. The role of protein kinase activity expressed by the UL13 gene of herpes simplex virus 1: The activity is not essential for optimal expression of UL41 and ICP0. Virology. 2005;341(2):301-312. doi: 10.1016/j.virol.2005.07.010

 

  1. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci. 2008;13:2060-2064. doi: 10.2741/2823

 

  1. Israyelyan A, Chouljenko VN, Baghian A, David AT, Kearney MT, Kousoulas KG. Herpes simplex virus type- 1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol J. 2008;5:68. doi: 10.1186/1743-422X-5-68

 

  1. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009;17(1):199-207. doi: 10.1038/mt.2008.228.

 

  1. Aghi MK, Chiocca EA. Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther. 2009;17(1):8-9. doi: 10.1038/mt.2008.275

 

  1. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001;98(11):6396-6401. doi: 10.1073/pnas.101136398

 

  1. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001;61(1):153-161.

 

  1. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res. 2006;12(2):643-652. doi: 10.1158/1078-0432.CCR-05-1494

 

  1. Lee CY, Bu LX, Rennie PS, Jia WWG. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther. 2007;14(7):652-660. doi: 10.1038/sj.cgt.7701052

 

  1. Kanai R, Tomita H, Hirose Y, et al. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum Gene Ther. 2007;18(1):63-73. doi: 10.1089/hum.2006.107

 

  1. Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, Nishiyama Y. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect. 2007;9(2):142-149. doi: 10.1016/j.micinf.2006.10.019

 

  1. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol. 2006;13(8):1078-1084. doi: 10.1245/ASO.2006.08.035

 

  1. Fujimoto Y, Mizuno T, Sugiura S, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 2006;126(10):1115-1117. doi: 10.1080/00016480600702100

 

  1. Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU, Chiocca EA, Breakefield XO. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol. 1998;451:393-403. doi: 10.1007/978-1-4615-5357-1_61

 

  1. Jacobs AH, Winkeler A, Hartung M, et al. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther. 2003;14(3):277-297. doi: 10.1089/10430340360535823

 

  1. Liu S, Dai M, You L, Zhao Y. Advance in herpes simplex viruses for cancer therapy. Sci China Life Sci. 2013;56(4):298-305. doi: 10.1007/s11427-013-4466-4

 

  1. Kim SH, Wong RJ, Kooby DA, et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer. 2005;41(2):313-322. doi: 10.1016/j.ejca.2004.10.018

 

  1. Jarnagin WR, Zager JS, Hezel M, et al. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 2006;13(3):326-334. doi: 10.1038/sj.cgt.7700890

 

  1. Adusumilli PS, Stiles BM, Chan MK, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg. 2005;80(2):409-416; discussion 416-7. doi: 10.1016/j.athoracsur.2005.01.048

 

  1. Liu BL, Robinson M, Han, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292-303. doi: 10.1038/sj.gt.3301885

 

  1. Hocknell PK, Wiley RD, Wang X, et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol. 2002;76(11):5565-5580. doi: 10.1128/jvi.76.11.5565-5580.2002

 

  1. Santos K, Duke CM, Dewhurst S. Amplicons as vaccine vectors. Curr Gene Ther. 2006;6(3):383-392. doi: 10.2174/156652306777592009

 

  1. Tyler CM, Wuertzer CA, Bowers WJ, Federoff HJ. HSV amplicons: Neuro applications. Curr Gene Ther. 2006;6(3):337-350. doi: 10.2174/156652306777592045

 

  1. Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. J Gene Med. 2002;4(3):229-239. doi: 10.1002/jgm.276

 

  1. Tsitoura E, Lucas M, Revol-Guyot V, Epstein AL, Manservigi R, Mavromara P. Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. J Gen Virol. 2002;83(Pt 3):561-566. doi: 10.1099/0022-1317-83-3-561

 

  1. Hong Z, Ferrari E, Wright-Minogue J, et al. Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol. 1996;70(7):4261-4268. doi: 10.1128/jvi.70.7.4261-4268.1996

 

  1. Watanabe D, Brockman MA, Ndung’u T, et al. Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology. 2007;357(2):186-198. doi: 10.1016/j.virol.2006.08.015

 

  1. Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol. 2005;79(1):410-418. doi: 10.1128/JVI.79.1.410-418.2005

 

  1. Lauterbach H, Kerksiek KM, Busch DH, et al. Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol. 2004;78(8):4020-4028. doi: 10.1128/jvi.78.8.4020-4028.2004

 

  1. Murphy CG, Lucas WT, Means RE, et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol. 2000;74(17):7745-7754. doi: 10.1128/jvi.74.17.7745-7754.2000

 

  1. Liu X, Broberg E, Watanabe D, Dudek T, Deluca N, Knipe DM. Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine. 2009;27(21):2760-2767. doi: 10.1016/j.vaccine.2009.03.003

 

  1. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A. 1999;96(6):3211-3216. doi: 10.1073/pnas.96.6.3211

 

  1. Goss JR, Harley CF, Mata M, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol. 2002;52(5):662-665. doi: 10.1002/ana.10343

 

  1. Berto E, Bozac A, Marconi P. Development and application of replication-incompetent HSV-1-based vectors. Gene Ther. 2005;12 Suppl 1:S98-S102. doi: 10.1038/sj.gt.3302623

 

  1. Chattopadhyay M, Krisky D, Wolfe D, Glorioso JC, Mata M, Fink DJ. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 2005;12(18):1377-1384. doi: 10.1038/sj.gt.3302533

 

  1. Bolognani F, Goya RG. Gene therapy in the neuroendocrine system: Its implementation in experimental models using viral vectors. Neuroendocrinology. 2001;73(2):75-83. doi: 10.1159/000054623

 

  1. Wolfe D, et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther. 2004;11(23):1675-1684. doi: 10.1038/sj.gt.3302336

 

  1. Perez MC, Hunt SP, Coffin RS, Palmer JA. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Ther. 2004;11(13):1023-1032. doi: 10.1038/sj.gt.3302258

 

  1. Walther W, Stein U. Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs. 2000;60(2):249-271. doi: 10.2165/00003495-200060020-00002

 

Share
Back to top
Microbes & Immunity, Electronic ISSN: 3029-2883 Print ISSN: 3041-0886, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept